ClinicalTrials.gg
CompletedNCT02333331Updated Jan 5, 2021Results posted

Dose Range Finding Study of Bimagrumab in Sarcopenia

A Phase 2 interventional study of bimagrumab and placebo in Sarcopenia, sponsored by Novartis Pharmaceuticals. Completed at 58 sites in 13 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Sarcopenia with a site in United States — 37 open to participants now, 47 under way, 1 of them phase 3. Sarcopenia · United States.

Enrollment
8th of 146
217 · median 40
Started
2014
with 12 others
Phase 2
20 of 187
5 open now
Registered
60th of 187
by date

Among the 187 studies in Sarcopenia with a site in United States, this one is the 8th largest by enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2014, is one of 20 in phase 2, and was the 60th registered.

Sarcopenia

1,330 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

37 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Sarcopenia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.

03

Conditions studied

  • Sarcopenia

Keywords

  • Sarcopenia, muscle wasting, elderly, strength, physical function, muscle, gait speed
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Low muscle mass as confirmed by DXA;
  • Low gait speed \<0.8 m/s
  • SPPB score less than or equal to 9;
  • Weigh at least 35 kg;
  • Adequate dietary intake;

Exclusion criteria

Exclusion Criteria:

  • A lower limb fracture in the past 6 months or any impairment or disease severely affecting gait (e.g. stroke with hemiparesis, myasthenia gravis, Parkinson's disease, peripheral polyneuropathy, intermittent claudication in advanced peripheral vascular disease, spinal stenosis, or severe osteoarthritis of the knee or hip with ineffective pain management);
  • Requires regular assistance from another person for general activities of daily living (e.g. bathing, dressing, toileting).
  • Intraocular surgery and laser procedures for refractive correction within 6 months prior to screening;
  • Any underlying muscle disease including active myopathy or muscular dytrophy;
  • Confirmed diagnosis of heart failure classified as Class III or IV (e.g. dilated cardiomyopathy);
  • Type I diabetes or uncontrolled Type 2 diabetes;
  • Chronic kidney disease [estimated (GFR) \< 30 mL/min];
  • History of confirmed with a severity grade > 2 on the Medical Research Council Dyspnea Scale;
  • Confirmed rheumatoid arthritis or other systemic disease requiring therapy or >10 mg/d prednisone equivalent;
  • Known history or presence of severe active acute or chronic liver disease (e.g., cirrhosis);
  • Myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention (e.g. angioplasty or stent placement), or deep vein thrombosis/pulmonary embolism within 12 weeks of screening;
  • Active cancer (i.e., under current treatment), or cancer requiring treatment in the last 5 years excluding non-melanoma skin cancers or cancers with excellent prognosis (e.g., early stage prostate or breast cancer, carcinoma in situ of the uterine cervix);
  • Any chronic active infection (e.g., , or C, tuberculosis, etc).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    BYM338 70 mg

    BYM338 70 mg intravenous infusion

    Drug: bimagrumab

  • Experimental
    BYM338 210 mg

    BYM338 210 mg intravenous infusion

    Drug: bimagrumab

  • Experimental
    BYM338 700 mg

    BYM338 700 mg intravenous infusion

    Drug: bimagrumab

  • Placebo comparator
    Placebo

    Placebo intravenous infusion

    Other: placebo

Interventions

  • Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

    Also known as: BYM338

  • Otherplacebo

    Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.

    Also known as: 5% dextrose

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25

    Change from Baseline in total Short Physical Performance Battery (SPPB) Score to week 25; SPPB is a series of six activities involving three domains of physical function - balance, usual walking speed and rising from a chair , is commonly used globally to assess and quantify (score 0-12) lower extremity function and has been shown to predict future adverse health events. A decline of one or more points in the SPPB total score is predictive of a decrease in lower extremity function and future adverse clinical outcomes in older adults, including falls, hospitalizations, institutionalization, incident disability and death

    Time frame: Baseline, week 25

Secondary outcomes

  1. Change From Baseline at Week 25 in the 6 Minute Walk Test (6MWT) Distance

    Change from Baseline at Week 25 in the 6 minute walk test (6MWT) distance to measure improvement in physical function

    Time frame: Baseline, week 25

  2. Change From Baseline to Week 25 in Usual Gait Speed (GS) Over 4 Meters

    Change from Baseline to Week 25 in usual Gait speed (GS) over 4 meters Gait speed in this study was assessed as part of the SPPB, over a 4 meter distance of a 6 meter course. This test assessed a person's usual walking speed, which was defined as the speed a person normally walks from one place to another without urgency (e.g., walking down a hallway).

    Time frame: baseline, week 25

  3. Percentage Change From Baseline to Week 25 on Appendicular Skeletal Muscle Index (ASMI) Measured by Dual Energy X-ray Absorptiometry (DXA)

    Change from Baseline to Week 25 on appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) Appendicular skeletal muscle index (ASMI) is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m\^2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.

    Time frame: baseline, week 25

  4. Percentage Change From Baseline to Week 25 on Total Lean Body Mass Measured by Dual Energy X-ray Absorptiometry (DXA)

    Change from Baseline to Week 25 on Total lean body mass and appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.

    Time frame: baseline, week 25

07

Results

Posted Aug 6, 2019

Participant flow

A total of 220 patients were randomized to receive six doses of either BYM338 70 mg, BYM338 210 mg, BYM338 700 mg or the placebo. However, only 217 patients were enrolled and dosed with BYM338 or placebo due to the withdrawal of three patients who did not meet the inclusion/exclusion criteria prior to receiving the first dose.

Participant flow — Overall Study
MilestoneBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Started191811367
Completed17129564
Not completed26183
Withdrew: Adverse event1041
Withdrew: Death0020
Withdrew: Lost to follow-up0010
Withdrew: Physician decision0100
Withdrew: Protocol deviation0321
Withdrew: Patient/guardian decision1291

Outcome measures

PrimaryChange From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25

Change from Baseline in total Short Physical Performance Battery (SPPB) Score to week 25; SPPB is a series of six activities involving three domains of physical function - balance, usual walking speed and rising from a chair , is commonly used globally to assess and quantify (score 0-12) lower extremity function and has been shown to predict future adverse health events. A decline of one or more points in the SPPB total score is predictive of a decrease in lower extremity function and future adverse clinical outcomes in older adults, including falls, hospitalizations, institutionalization, incident disability and death

Time frame:
Baseline, week 25
Reported as:
Mean · Score on a scale
Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25
Score on a scaleBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Baseline7.1 ± 2.127.3 ± 2.117.2 ± 1.637.3 ± 1.67
Week 258.5 ± 2.488.7 ± 1.648.7 ± 2.128.4 ± 2.25
Statistical analysis
  • BYM338 70 mg vs Placebo · Mixed Models Analysis · p = 0.274 · Mean difference (final values): 0.28 · 95% CI -0.64 to 1.21
  • BYM338 210 mg vs Placebo · Mixed Models Analysis · p = 0.320 · Mean difference (final values): 0.26 · 95% CI -0.83 to 1.35
  • BYM338 700 mg vs Placebo · Mixed Models Analysis · p = 0.134 · Mean difference (final values): 0.31 · 95% CI -0.24 to 0.87
SecondaryChange From Baseline at Week 25 in the 6 Minute Walk Test (6MWT) Distance

Change from Baseline at Week 25 in the 6 minute walk test (6MWT) distance to measure improvement in physical function

Time frame:
Baseline, week 25
Reported as:
Mean · meters
Change From Baseline at Week 25 in the 6 Minute Walk Test (6MWT) Distance
metersBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Baseline293.30 ± 91.842291.81 ± 82.527294.30 ± 83.602312.43 ± 93.924
Week 25304.98 ± 102.934340.71 ± 72.911315.32 ± 97.020322.71 ± 103.865
Statistical analysis
  • BYM338 70 mg vs Placebo · Mixed Models Analysis · p = 0.576 · Mean difference (final values): -3.32 · 95% CI -37.6 to 30.95
  • BYM338 210 mg vs Placebo · Mixed Models Analysis · p = 0.178 · Mean difference (final values): 19.60 · 95% CI -22.2 to 61.41
  • BYM338 700 mg vs Placebo · Mixed Models Analysis · p = 0.163 · Mean difference (final values): 10.31 · 95% CI -10.4 to 30.98
SecondaryChange From Baseline to Week 25 in Usual Gait Speed (GS) Over 4 Meters

Change from Baseline to Week 25 in usual Gait speed (GS) over 4 meters Gait speed in this study was assessed as part of the SPPB, over a 4 meter distance of a 6 meter course. This test assessed a person's usual walking speed, which was defined as the speed a person normally walks from one place to another without urgency (e.g., walking down a hallway).

Time frame:
baseline, week 25
Reported as:
Mean · m/sec
Change From Baseline to Week 25 in Usual Gait Speed (GS) Over 4 Meters
m/secBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Baseline2.37 ± 0.6842.72 ± 0.7522.58 ± 0.6242.70 ± 0.493
Week 253.12 ± 0.8573.60 ± 0.6993.30 ± 0.9023.23 ± 0.838
Statistical analysis
  • BYM338 70 mg vs Placebo · Mixed Models Analysis · p = 0.488 · Mean difference (net): 0.00 · 95% CI -0.10 to 0.10
  • BYM338 210 mg vs Placebo · Mixed Models Analysis · p = 0.055 · Mean difference (net): 0.10 · 95% CI -0.02 to 0.22
  • BYM338 700 mg vs Placebo · Mixed Models Analysis · p = 0.161 · Mean difference (net): 0.03 · 95% CI -0.03 to 0.09
SecondaryPercentage Change From Baseline to Week 25 on Appendicular Skeletal Muscle Index (ASMI) Measured by Dual Energy X-ray Absorptiometry (DXA)

Change from Baseline to Week 25 on appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) Appendicular skeletal muscle index (ASMI) is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m\^2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.

Time frame:
baseline, week 25
Reported as:
Mean · Percent Change
Percentage Change From Baseline to Week 25 on Appendicular Skeletal Muscle Index (ASMI) Measured by Dual Energy X-ray Absorptiometry (DXA)
Percent ChangeBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Baseline5.99 ± 0.8865.87 ± 0.7955.70 ± 0.8235.55 ± 0.753
Week 256.04 ± 0.9476.42 ± 0.8496.10 ± 0.8365.60 ± 0.717
Statistical analysis
  • BYM338 70 mg vs Placebo · Mixed Models Analysis · p = 0.213 · Mean difference (net): 1.01 · 95% CI 0.99 to 1.03
  • BYM338 210 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): 1.06 · 95% CI 1.03 to 1.09
  • BYM338 700 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): 1.06 · 95% CI 1.05 to 1.08
SecondaryPercentage Change From Baseline to Week 25 on Total Lean Body Mass Measured by Dual Energy X-ray Absorptiometry (DXA)

Change from Baseline to Week 25 on Total lean body mass and appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.

Time frame:
baseline, week 25
Reported as:
Mean · Percent Change
Percentage Change From Baseline to Week 25 on Total Lean Body Mass Measured by Dual Energy X-ray Absorptiometry (DXA)
Percent ChangeBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Baseline37.44 ± 8.50735.84 ± 7.30035.39 ± 8.89133.65 ± 6.890
Week 2538.26 ± 8.66039.52 ± 8.34337.86 ± 9.06433.95 ± 6.921
Statistical analysis
  • BYM338 70 mg vs Placebo · Mixed Models Analysis · p = 0.458 · Mean difference (net): 1.00 · 95% CI 0.98 to 1.02
  • BYM338 210 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): 1.05 · 95% CI 1.03 to 1.08
  • BYM338 700 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): 1.06 · 95% CI 1.04 to 1.07

Adverse events

Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 25 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYM338 70 mg0/19 (0%)0/19 (0%)12/19 (63.2%)
BYM338 210 mg0/18 (0%)3/18 (16.7%)13/18 (72.2%)
BYM338 700 mg2/113 (1.8%)14/113 (12.4%)94/113 (83.2%)
Placebo0/67 (0%)5/67 (7.5%)41/67 (61.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
Myocardial infarctionCardiac disorders0/191/180/1130/67
Spinal fractureInjury, poisoning and procedural complications0/191/180/1130/67
Blood alkaline phosphatase increasedInvestigations0/191/180/1130/67
MyalgiaMusculoskeletal and connective tissue disorders0/191/180/1130/67
Colitis ulcerativeGastrointestinal disorders0/190/180/1131/67
Anaphylactic reactionImmune system disorders0/190/180/1131/67
InfluenzaInfections and infestations0/190/180/1131/67
Back painMusculoskeletal and connective tissue disorders0/190/180/1131/67
Neck painMusculoskeletal and connective tissue disorders0/190/180/1131/67
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/190/180/1131/67
Most frequent other events
Showing 10 of 75
Most frequent other events
EventBYM338 70 mgBYM338 210 mgBYM338 700 mgPlacebo
FallInjury, poisoning and procedural complications2/193/1828/11324/67
Muscle spasmsMusculoskeletal and connective tissue disorders4/195/1837/11310/67
DiarrhoeaGastrointestinal disorders1/193/1822/1132/67
AcneSkin and subcutaneous tissue disorders0/193/183/1130/67
NasopharyngitisInfections and infestations3/191/185/1130/67
Upper respiratory tract infectionInfections and infestations1/192/185/1135/67
Back painMusculoskeletal and connective tissue disorders1/192/185/1133/67
BradycardiaCardiac disorders2/190/183/1130/67
VertigoEar and labyrinth disorders2/190/181/1132/67
ContusionInjury, poisoning and procedural complications0/191/185/1137/67

Baseline characteristics

Age, Continuous
Age, Continuous(years)BYM338 70 mgBYM338 210 mgBYM338 700 mgPlaceboTotal
Mean79.3 ± 5.8978.0 ± 6.3879.5 ± 5.4678.3 ± 5.0379.0 ± 5.45
Sex: Female, Male
Sex: Female, Male(Participants)BYM338 70 mgBYM338 210 mgBYM338 700 mgPlaceboTotal
Female986643126
Male1010472491
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BYM338 70 mgBYM338 210 mgBYM338 700 mgPlaceboTotal
American Indian or Alaska Native00101
Asian53171136
Native Hawaiian or Other Pacific Islander00101
Black or African American30014
White11149354172
More than one race00011
Unknown or Not Reported01102
08

Study locations

58 sites
  • Novartis Investigative Site
    Little Rock, Arkansas 72205, United States
  • Novartis Investigative Site
    Cypress, California 90630, United States
  • Novartis Investigative Site
    La Jolla, California 92093-9405, United States
  • Novartis Investigative Site
    Farmington, Connecticut 06030-5215, United States
  • Novartis Investigative Site
    Gainesville, Florida 32611, United States
  • Novartis Investigative Site
    Miami Lakes, Florida 33014, United States
  • Novartis Investigative Site
    Miami, Florida 33143, United States
  • Novartis Investigative Site
    Orlando, Florida 32804, United States
  • Novartis Investigative Site
    Gainesville, Georgia 30501, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Rochester, Minnesota 55905, United States
  • Novartis Investigative Site
    High Point, North Carolina 27262, United States
  • Novartis Investigative Site
    Columbus, Ohio 43210, United States
  • Novartis Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Novartis Investigative Site
    Mesquite, Texas 75150, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Madison, Wisconsin 53706, United States
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    St Albans, Victoria 3021, Australia
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Brno, 62500, Czechia
  • Novartis Investigative Site
    Opava, 74601, Czechia
  • Novartis Investigative Site
    Praha 2, 12000, Czechia
  • Novartis Investigative Site
    Copenhagen NV, 2400, Denmark
  • Novartis Investigative Site
    Copenhagen, 2100, Denmark
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Toulouse, 31052, France
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Wuerzburg, 97074, Germany
  • Novartis Investigative Site
    Obu-city, Aichi 474-8511, Japan
  • Novartis Investigative Site
    Toyohashi-city, Aichi 440-8510, Japan
  • Novartis Investigative Site
    Mizunami-city, Gifu 509 6134, Japan
  • Novartis Investigative Site
    Nara-city, Nara 630-8581, Japan
  • Novartis Investigative Site
    Kawachinagano-city, Osaka 586-8521, Japan
  • Novartis Investigative Site
    Kitaadachigun Inamachi, Saitama 362-0806, Japan
  • Novartis Investigative Site
    Kitamoto-city, Saitama 364-8501, Japan
  • Novartis Investigative Site
    Yoshinogawa-city, Tokushima 776-8585, Japan
  • Novartis Investigative Site
    Itabashi ku, Tokyo 173 0015, Japan
  • Novartis Investigative Site
    Kiyose-city, Tokyo 204-0021, Japan
  • Novartis Investigative Site
    Koto-ku, Tokyo 136-0075, Japan
  • Novartis Investigative Site
    Musashimurayama-city, Tokyo 208-0011, Japan
  • Novartis Investigative Site
    Bundang Gu, Gyeonggi Do 13620, Korea, Republic of
  • Novartis Investigative Site
    Suwon si, Gyeonggi Do 16499, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 02447, Korea, Republic of
  • Novartis Investigative Site
    Moscow, 101990, Russian Federation
  • Novartis Investigative Site
    Moscow, 117997, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 190068, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150003, Russian Federation
  • Novartis Investigative Site
    Albacete, Castilla La Mancha 02006, Spain
  • Novartis Investigative Site
    Getafe, Madrid 28905, Spain
  • Novartis Investigative Site
    Barcelona, 08024, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Basel, CH 4002, Switzerland
  • Novartis Investigative Site
    Genève 14, 1211, Switzerland
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N, Coleman LA, Miller RR, Garcia Garayoa E, Praestgaard J, Perry RG, Recknor C, Fogarty CM, Arai H, Chen LK, Hashimoto J, Chung YS, Vissing J, Laurent D, Petricoul O, Hemsley S, Lach-Trifilieff E, Papanicolaou DA, Roubenoff R. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2020 Oct 1;3(10):e2020836. doi: 10.1001/jamanetworkopen.2020.20836. PubMed 33074327 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jun 2018, 42 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2014
First posted
Jan 7, 2015
StartActual
Dec 9, 2014
Primary completionActual
Jun 26, 2018
CompletionActual
Jun 28, 2018
Results first posted
Aug 6, 2019
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02333331
Responsible party
Sponsor
First posted
Jan 7, 2015
Start date
Dec 9, 2014
Primary completion
Jun 26, 2018
Completion
Jun 28, 2018
Results posted
Aug 6, 2019
Last update
Jan 5, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion